Gilead Sciences, Inc. has updated on the clinical program for two experimental HIV-1 medicines: GS-1720, a new nucleoside reverse transcriptase translocation inhibitor (NRTTI), and GS-4182, a potent capsid inhibitor. These compounds are being tested as part of a multi-pronged approach to develop long-acting HIV medicines.
In accordance with Gilead, though these drugs have been found to possess antiviral activity in phase-1 trials, the Phase 1b trials currently ongoing have brought to light tolerability issues such as injection-site reactions and elevated liver enzymes among some of the participants. Therefore, the company has suspended dosing in these trials to enable an intensive review of the safety data coming in.
GS-1720 and GS-4182 were being investigated as potential long-acting injectable regimens to reduce the burden of once-daily medication for HIV patients, both in combination and as monotherapy. The plan aligns with Gilead’s long-term commitment to HIV treatment innovation and its pipeline initiatives towards sustainable, efficient regimens.
Gilead emphasized that trial participants are continuously monitored and that no significant side effects have been directly linked to the investigational medications. The company is carrying out more evaluations and will make a decision regarding the products’ future development after consulting with independent specialists and regulatory officials.
The statement demonstrates the open communication of Gilead with the scientific community and impacted stakeholders, and the company reiterates its commitment to creating transformative medicines for individuals with HIV.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
